Georgia Depo-Provera Lawsuit Lawyer: Meningioma Claims

Written by Fob James IV, Esq. | Fob James Law Firm, LLC | Last Updated: June 15, 2026

The Depo-Provera lawsuit lawyers at Fob James Law Firm are representing women across Georgia who were diagnosed with a meningioma brain tumor after using Pfizer’s popular birth control shot.

The country is witnessing a surge in Depo-Provera lawsuits as individuals step forward, alleging serious side effects associated with the contraceptive injection, including a potential link to meningioma.

The crux of the Depo-Provera lawsuit is that Pfizer and other drug companies failed to adequately warn women that using their birth control shot increases the chance of developing meningioma brain tumors by over 5 times.

At Fob James Law Firm, we want to provide a clear understanding of the Depo-Provera lawsuit, what the claims involve, and how those affected can seek legal assistance.

If you or a loved one was diagnosed with a meningioma, contact our experienced Depo-Provera lawyers in Atlanta, Georgia for a free case evaluation.

Please don’t hesitate to reach out to us 24/7 at 866-837-1010.

Georgia Depo-Provera Lawsuit Quick Facts

Why Our Georgia Depo-Provera Lawyers Are the Top Choice

When you search for a Depo-Provera lawyer in Georgia, you’ll see ads from national lead-generation firms and out-of-state mass-tort shops. Fob James Law Firm is different: we maintain an Atlanta office, serve Georgia clients directly, and charge a 33–40% contingency fee — not the 45% many national firms charge.

For more than 40 years, the attorneys at Fob James Law Firm have been fighting for victims of drug injuries across the country.

• We work closely with each of our clients, ensuring they receive personalized attention.
• With our firm, you will actually speak with your dedicated lawyer — not an assistant.
• Comprehensive medical record evaluations by top specialists.
• Deep experience in pharmaceutical and mass tort litigation, including active participation in the Depo-Provera MDL.
• Real federal and state courtroom experience, serving Georgia families from our Atlanta office.
• Backed by the power and resources of national drug-injury litigation.
• Contingency fee representation — pay nothing unless we win.
• Lower fees than most firms: we charge a 33–40% contingency fee, compared to the 45% many other firms charge in the Depo-Provera litigation.
• We handle Depo-Provera cases in all 50 states.

About the author: Fob James IV is the managing attorney of Fob James Law Firm and a Vanderbilt Law graduate recognized by the National Trial Lawyers Top 100 and as a SuperLawyers Rising Star (2020–2025). He represents clients in pharmaceutical and mass-tort litigation nationwide, including the Depo-Provera MDL, and serves Georgia families from the firm’s Atlanta office.

Our case results and client testimonials speak for themselves. Call us today to schedule your free consultation and case review.

What Are the Problems With Depo-Provera?

Depo-Provera is a contraceptive drug made by Pfizer containing the progestin hormone. The generic version of the birth control shot is made by Mylan N.V.

The contraceptive shot is administered in the arm or buttocks every three months. The shot’s active ingredient, medroxyprogesterone acetate, prevents pregnancy by stopping ovulation.

The convenience of this contraceptive shot has made it a preferred choice for many women, but it is not without risk. While effective, Depo-Provera has been associated with several side effects, some of which can be severe.

The mechanism by which Depo-Provera functions involves altering the hormonal balance within the body, which can lead to a range of physical problems.

Many women experience severe side effects from Depo-Provera, including:

• menstrual irregularities,
• headaches,
• bone density loss,
• blood clots,
• osteoporosis,
• increased risk of breast cancer, and
• meningioma brain tumors.

The most alarming side effect is meningioma, a usually benign but sometimes dangerous brain tumor. Depo-Provera elevates progesterone levels in women, which can stimulate tumor growth in the brain.

Studies suggest that Depo-Provera increases the risk of developing meningioma brain tumors, leading to lawsuits from affected individuals in Georgia and across the country.

What Is a Meningioma Brain Tumor?

The growing concerns about Depo-Provera have led to numerous lawsuits. In Georgia, there is a particular interest in cases involving meningioma, which has emerged as a significant health concern.

Meningioma is a tumor that develops in the protective membranes that surround the brain and spinal cord. While often benign, it can cause severe neurological damage, blindness, and even death.

Common symptoms of meningioma tumors include:

• Changes in vision, such as seeing double or blurriness
• Headaches that worsen with time
• Hearing loss or ringing in the ears
• Memory loss
• Loss of smell
• Seizures
• Weakness in your arms or legs

Meningioma tumors are typically graded I through III based on their severity:

• Grade I: A non-cancerous tumor that grows very slowly
• Grade II: Non-cancerous but more rapidly growing tumors that may require surgery or radiation treatment
• Grade III: Rare cancerous tumors that grow fast and aggressively

What Is the Depo-Provera Lawsuit About?

Pfizer and other manufacturers of Depo-Provera have been sued for the simple fact that their birth control shots allegedly increase the risk of developing a brain tumor. The Depo-Provera lawsuits are primarily based on two theories: (i) failure to warn and (ii) design defect.

Pfizer’s Failure to Warn

The Depo-Provera lawsuits in Georgia argue that Pfizer failed to adequately warn consumers about the risk of developing meningioma brain tumors and other severe side effects after using the popular contraceptive injections.

Despite having knowledge of the risks, the Depo-Provera lawsuits allege Pfizer aggressively marketed their birth control shots as a safe alternative to other birth control drugs.

Depo-Provera’s Design Defects

Moreover, the Depo-Provera lawsuits allege that the design of the drug was defective, particularly the high dose of progestin, which can cause meningioma tumors.

The Depo-Provera lawsuits further allege that Pfizer negligently failed to formulate the birth control shots in a way that would not increase the risk of brain tumors.

Georgia plaintiffs are seeking compensation, including medical expenses, lost wages, and pain and suffering.

To discuss the specific claims in your case, call a compassionate Georgia Depo-Provera lawyer for a free case review.

Who Qualifies for the Depo-Provera Lawsuit in Georgia?

Women in Georgia diagnosed with a meningioma tumor after using the birth control shots listed below may qualify for the Depo-Provera lawsuit:

• Depo-Provera (Pfizer),
• Depo-SubQ (Pfizer), or
• Generic version of Depo-Provera (Mylan N.V.)

In most cases that qualify, the claimant used Depo-Provera for at least one to two years before a meningioma diagnosis. You must have an image-confirmed diagnosis (MRI or CT scan) of a cranial or spinal meningioma. Key evidence includes pharmacy records, medical records documenting injections, and imaging reports confirming the diagnosis.

It does not matter where in Georgia you live. Georgia is one of the most active states in the Depo-Provera litigation, and our Atlanta office puts us close to Georgia’s federal courts. We represent Depo-Provera victims in Atlanta, Savannah, Augusta, Columbus, Macon, Athens, and across the state — and in all 50 states. To see if your case qualifies, contact Fob James Law Firm today.

Does Depo-Provera Cause Meningioma? The Science Is Real

British Medical Journal Study

In March 2024, the British Medical Journal released a study analyzing data from more than 18,000 women in France who underwent surgery for meningiomas between 2009 and 2018.

The researchers found that women who had used Depo-Provera for more than one year were over 5.6 times more likely to develop meningioma brain tumors than women who either did not use the drug or used it for a short period of time.

The bottom line is that the study concludes the use of injectable medroxyprogesterone acetate increases the risk of developing meningioma.

BMJ 2024;384:e078078

University of British Columbia Study

On February 2, 2025, researchers with the University of British Columbia released a study reflecting that using Depo-Provera causes meningioma.

Specifically, the researchers found that taking medroxyprogesterone acetate for at least one year increases the risk of meningioma by more than 3.55 times.

Journal of the American Medical Association – September 2025 Study

The Journal of the American Medical Association published a study linking Depo-Provera to brain tumors. The study is quite damaging to Pfizer. Roughly 10 million women were part of the study, which found a 2.43-fold risk increase in brain tumors among women who took Depo-Provera versus women who did not take the birth control shot.

Expert Opinion on Drug Safety – August 2025 Study

A study published in Expert Opinion on Drug Safety in August 2025 found that use of Pfizer’s Depo-Provera for more than one year is associated with a 3.5-fold increased risk of developing an intracranial meningioma compared with the use of oral birth control pills. The study concluded that Depo-Provera’s active ingredient “is linked to a substantially increased risk of meningiomas.”

The science for the causal link between Depo-Provera and meningioma is still evolving, and we expect more studies in 2026. Notably, the general-causation Daubert/Rule 702 hearing is set for June 24–26, 2026, where Judge Rodgers will evaluate whether plaintiffs’ experts may testify that Depo-Provera causes meningioma — a ruling that, under Pretrial Order No. 30, will apply to every pending Georgia case at once.

Georgia Depo-Provera Lawsuit FAQ

Has the FDA Recalled Depo-Provera?

No, the FDA has not recalled Depo-Provera. However, there have been two significant regulatory actions. The FDA has long required a “black box warning” about the risk of bone density loss and osteoporosis, and recommends that women use Depo-Provera no more than two years.

Most importantly for the current litigation, in December 2025 the FDA approved a new warning label that specifically warns about the risk of meningioma brain tumors with repeated or long-term use. This was the first time the U.S. label acknowledged the meningioma risk — years after Canada and European countries had already required similar warnings. Plaintiffs argue this delay supports their failure-to-warn claims.

Is There a Depo-Provera Class Action Lawsuit?

The Depo-Provera litigation is a multidistrict litigation (MDL No. 3140), not a class action. Each plaintiff files an individual lawsuit, but all cases are consolidated before Judge M. Casey Rodgers in the Northern District of Florida. As of June 2026, more than 5,500 lawsuits have been filed in the MDL, with new cases filed at roughly 650 per month. In an MDL, each case is evaluated individually, so your settlement will depend on the specific facts of your case.

How Many Depo-Provera Lawsuits Have Been Filed?

As of June 2026, more than 5,500 Depo-Provera lawsuits have been filed in the federal MDL (No. 3140) in the Northern District of Florida — up from roughly 2,098 in February 2026, a filing pace of about 650 new cases per month. Hundreds of additional cases are pending in state courts. Plaintiffs’ attorneys report holding thousands of additional unfiled claims under evaluation.

Can I Still File a Depo-Provera Lawsuit in 2026?

Yes. New cases are being filed every month, and the litigation is still in its pretrial stages — following a June 2026 settlement agreement, the first bellwether trial was placed on hold and the Rule 702 (Daubert) causation hearing was rescheduled to July 27, 2026 in Pensacola. In Georgia, you generally have two years from the date you discovered your injury to file, subject to a 10-year statute of repose. The discovery rule may extend this, but you should contact an attorney as soon as possible to protect your claim.

What Can I Recover From a Georgia Depo-Provera Lawsuit?

Every case is unique, but plaintiffs who file a Depo-Provera lawsuit can recover money for the following damages:

• Past and future medical bills (including medication, hospital stays, and in-home care)
• Pain and suffering
• Lost wages
• Loss of earning capacity
• Funeral expenses (in the event of a loved one’s death)
• Broadly speaking, a plaintiff could be entitled to compensation for any past and future costs associated with their meningioma diagnosis

If your loved one died as a result of their meningioma, you may be able to file a wrongful death lawsuit.

What Is the Cost to Hire a Depo-Provera Lawyer in Georgia?

Fob James Law Firm operates on a contingency-fee basis in the Depo-Provera lawsuits. This means we only get paid a percentage of the recovery if we successfully resolve your case.

Our fees come out of a favorable settlement or jury award, not out of your pocket. If we do not obtain a recovery, then you owe us nothing.

Many clients have told us that other firms are charging 45% contingency fees in the Depo-Provera litigation. However, Fob James Law Firm charges Depo-Provera lawsuit clients a 33–40% contingency fee.

To speak with our experienced Georgia Depo-Provera lawsuit lawyers, call us today at 866-837-1010.

How Long Do I Have to File a Depo-Provera Lawsuit in Georgia?

The time to file a claim is known as the statute of limitations (“SOL”). The SOL is complicated and every state is different, so make sure you consult with an attorney about how long you have to file a lawsuit.

In Georgia, under O.C.G.A. § 9-3-33, you generally have two years from the date you discovered (or reasonably should have discovered) your Depo-Provera-related injury to file a lawsuit. Georgia also imposes a 10-year statute of repose on product liability claims under O.C.G.A. § 51-1-11(b), which can set an outer limit regardless of the discovery rule. Because the link between Depo-Provera and meningioma only became widely known after the March 2024 BMJ study, the discovery rule is especially important for many Georgia plaintiffs.

However, for cases involving minors, the statute of limitations in Georgia “tolls” until the injured minor is 18 years old. On their 18th birthday, the claimant has two years to file a lawsuit against the negligent party.

In the context of a wrongful death claim, the personal representative of the deceased victim has two years from the date of the victim’s death to file a lawsuit.

Do not assume that you have ample time to file your claim. Contact our Depo-Provera lawyers in Georgia to discuss filing deadlines in your case.

How Do I Join the Depo-Provera Lawsuit in Georgia?

It is simple to join the Depo-Provera lawsuit. Call us today or submit your contact information and our attorneys will contact you to discuss your case.

It does not matter where you live. We represent victims of Depo-Provera birth control shots in all 50 states.

When Will the Georgia Depo-Provera Lawsuit Be Settled?

The Depo-Provera cases were consolidated into a multidistrict litigation (MDL No. 3140) before Judge M. Casey Rodgers in the Northern District of Florida in February 2025, and the litigation has moved at a record pace since. On June 15, 2026, the parties announced a global settlement agreement in principle. The terms and eligibility criteria have not yet been released, and the agreement is not expected to resolve every case.

As a result of the settlement, the first bellwether trial — previously scheduled for December 7, 2026 — was placed on hold, and the general-causation Rule 702 (Daubert) hearing was rescheduled to July 27, 2026 in Pensacola. The timeline for final resolution will depend on the settlement’s terms and the court’s approval process.

Because eligibility and filing deadlines may affect participation in any settlement, Georgia women who used Depo-Provera and were later diagnosed with a meningioma should have their claims evaluated promptly. Our best estimate for full resolution is within 2–4 years.

What Is the Average Settlement for a Depo-Provera Lawsuit?

The average Depo-Provera lawsuit settlement is difficult to determine because every case is unique. Many factors go into the value of the case, including the severity and permanency of the injuries, whether the plaintiff had surgery, the total cost of medical treatment (including future expenses), the age of the plaintiff, pain and suffering, and the venue where the case is litigated.

That being said, we believe three key factors weigh toward higher settlement values in Depo-Provera lawsuits compared to other mass torts:

Until bellwether trials occur, it is near impossible to estimate case values. Taking this with a grain of salt, our best estimate is that most Depo-Provera cases will settle in the $200,000 to $500,000+ range.

To discuss your Depo-Provera case value, schedule a free consultation with our experienced Georgia Depo-Provera lawyers today.

Depo-Provera MDL Litigation Updates

Last Updated: June 15, 2026

Updates on the Depo-Provera meningioma lawsuit are posted in this section throughout the litigation. We strive to post an update at least once per month. If you have questions about litigation updates, feel free to call us 24/7 at 866-837-1010.

June 15, 2026 – Global Settlement Agreement Reached in the Depo-Provera MDL

On June 15, 2026, the parties announced a global settlement agreement in principle to resolve claims in the Depo-Provera MDL (No. 3140) before Judge M. Casey Rodgers. The terms and eligibility criteria have not been made public, and the agreement is not expected to resolve every pending case. As a result of the settlement, the court placed the first bellwether trial — previously scheduled for December 7, 2026 — on hold and vacated the related deadlines, and the general-causation Rule 702 (Daubert) hearing was rescheduled from June 24–26 to a single date of July 27, 2026 in Pensacola. Georgia women who used Depo-Provera and were later diagnosed with a meningioma should have their claims evaluated promptly, as eligibility and filing deadlines may affect participation in any settlement.

June 11, 2026 – Daubert Causation Hearing Set for June 24–26 as MDL Surpasses 5,500 Cases

The Depo-Provera MDL has reached its most consequential stage yet. The three-day Daubert/Rule 702 hearing on general causation is now set for June 24–26, 2026, where Judge Rodgers will decide whether the plaintiffs’ scientific experts may testify that Depo-Provera causes meningioma — the gateway question for the entire litigation. Because Pretrial Order No. 30 makes the ruling applicable to every case in the MDL, the outcome will affect all pending Georgia claims at once.

The litigation also continues its record growth. More than 5,500 cases are now pending in MDL 3140 — up from roughly 2,098 in February — with new lawsuits being filed at a pace of approximately 650 per month. Pfizer’s federal preemption motion remains fully briefed and awaiting a ruling that could come at any time, and the next Case Management Conference is set for June 26, 2026.

For Georgia women diagnosed with a meningioma after using Depo-Provera, this litigation is moving faster than almost any mass tort in recent history — and the sooner you file, the better positioned your claim will be. Contact our Depo-Provera lawyers today at 866-837-1010 for a free case review.

May 15, 2026 – Daubert Hearing Continued to June; Case Count Climbs Past 3,500

At the May 15, 2026 Case Management Conference, the Court confirmed the schedule for the upcoming general-causation proceedings. The Rule 702/Daubert hearing originally targeted for May 26–28, 2026 was reset to June 24–26, 2026, giving the parties additional time to complete expert briefing, which was fully submitted by the end of May.

The MDL continued its rapid expansion through the spring, climbing past 3,400 pending cases in April (per JPML statistics) and continuing to grow at roughly 650 new filings per month on its way toward 5,000-plus by early summer. Pfizer’s federal preemption motion — which now must contend with the December 2025 FDA label change that added the very meningioma warning plaintiffs say was missing for years — remained under submission and awaiting a decision from Judge Rodgers.

April 2, 2026 – Depo-Provera Litigation Continues to Move at Record Pace

The Depo-Provera MDL is not just shaping up to be a significant litigation for the thousands of women injured by this drug — it is becoming a roadmap for how to move a complex MDL at rapid pace.

Discovery is wrapping up, and the Daubert hearing on general causation is now set for June 24–26, 2026 (continued from the original May 26–28 date). The Court is doing everything in its power to hold the December 7, 2026 bellwether trial date. All signs suggest it will.

Consider the timeline. The MDL was formed on February 7, 2025. In just over a year, Judge Rodgers has given us a master class in how to streamline mass tort litigation. We will have rulings on both federal preemption and expert causation within the first 18 months of the MDL’s formation. We will have a trial in under 20 months. And this is not a small litigation — the Depo-Provera MDL is the fastest-growing MDL of 2026. We expect 8,000 or more cases to be filed by the end of the year.

The question now is whether we could see a resolution of a contested MDL within two and a half years of formation. If that happens, it would be one of the most significant developments in mass tort history and a testament to Judge Rodgers’ management of this case.

For Georgia women who have been diagnosed with a meningioma after using Depo-Provera, the pace of this litigation is good news. A faster trial means a faster path to accountability and compensation. Contact our Depo-Provera lawyers today at 866-837-1010 for a free case review.

March 2, 2026 – Next CMC Rescheduled to March 6, 2026

Because of a scheduling conflict, Judge Rodgers cancelled the February 20, 2026, Case Management Conference. The Eleventh CMC will now take place on March 6, 2026. As a result, the previously scheduled March 13, 2026, CMC has also been cancelled. The parties were required to submit a Joint Agenda Letter by 12:00 p.m. CT on Monday, March 2, 2026, to the MDL court as well as to the courts overseeing related state-court proceedings in New York, Delaware, and California.

February 5, 2026 – Pfizer Files Supplemental Preemption Brief

Pfizer filed its supplemental brief arguing that Depo-Provera failure-to-warn claims are preempted by federal law. This brief addresses the December 2025 FDA label change — which added the meningioma warning — and how it impacts Pfizer’s preemption defense. Plaintiffs’ response was due February 20, 2026, with Pfizer’s reply due February 27, 2026. The outcome of this motion could be decisive: if Pfizer wins on preemption, many or all cases could be dismissed. We remain optimistic about the plaintiffs’ position, particularly now that the FDA has approved the very warning that plaintiffs argued should have been on the label for years.

January 27, 2026 – Pretrial Order No. 30 Applies Rulings MDL-Wide

Judge Rodgers entered Pretrial Order No. 30, clarifying that her upcoming rulings on federal preemption and expert causation (Daubert) will apply across the entire MDL — not just the five pilot cases. This is significant because it means a favorable ruling for plaintiffs on these issues will benefit every pending case in the MDL. The order also confirmed the litigation schedule: if Pfizer loses on preemption, the case moves directly into Rule 702 hearings on general causation (originally set for May 26–28, 2026, later continued to June 24–26, 2026).

January 20, 2026 – First Bellwether Trial Scheduled in December 2026

Judge Rodgers tentatively scheduled the first bellwether trial in the Depo-Provera MDL for December 7, 2026. If this date holds, this will be one of the fastest trial schedules in mass tort litigation history, reflecting Judge Rodgers’ commitment to moving this case efficiently. The five pilot cases are:

• Allison Blonski v. Pfizer Inc. (Case No. 3:25cv-00167)
• Donna Toney v. Pfizer Inc. (Case No. 3:24cv624)
• Alicia Wilson v. Pfizer Inc. (Case No. 3:25cv100)
• Kristina Schmidt v. Pfizer Inc. (Case No. 3:25cv81)
• Rachel Valera-Arceo v. Pfizer Inc. (Case No. 3:25cv98)

December 17, 2025 – FDA Approves Brain Tumor Warning

In a major development for the Depo-Provera litigation, the U.S. Food & Drug Administration (FDA) approved a new warning label for Pfizer’s Depo-Provera birth control shot that alerts patients and healthcare providers to the increased risk of meningiomas with long-term or repeated use. This update marks the first time the FDA has formally recognized meningioma risk on the product label, aligning U.S. prescribing information more closely with warnings already used in other countries.

The updated label now states that cases of meningiomas have been reported with repeated or long-term Depo-Provera use, and urges clinicians to monitor for symptoms and counsel patients accordingly. The FDA’s action could significantly impact the ongoing multidistrict litigation (MDL) and individual claims by strengthening plaintiffs’ arguments that the risk was known but not properly communicated for years.

November 3, 2025 – Depo-Provera Lawsuit Tally Passes 1,200

The multidistrict litigation (MDL) in the Pfizer Inc.-manufactured Depo-Provera (medroxyprogesterone acetate) case continues to advance. As of November 2025, more than 1,200 women have filed claims alleging the contraceptive shot led to intracranial meningiomas. We expect a lot more lawsuit filing activity if Judge Rodgers denies Pfizer’s motion to dismiss.

October 3, 2025 – Preemption Motion Waiting Game

On September 29th, Judge Rodgers heard oral arguments in Pensacola on Pfizer’s motion to dismiss the Depo-Provera lawsuits. A ruling is expected within the next 30 to 60 days. If the Judge rules for Pfizer, many or all of the cases could be dismissed. While Judge Rodgers did not indicate how she may decide, we remain optimistic about the plaintiffs’ chances.

September 4, 2025 – MDL Case Count Surges and Key Upcoming Hearing

As of September 2, 2025, the multidistrict litigation (MDL No. 3140) consolidating Depo-Provera brain tumor lawsuits has grown to 806 cases, up dramatically from 550 in August and 435 in July.

A pivotal motion to dismiss hearing is set for September 29, 2025, where Judge M. Casey Rodgers will consider Pfizer’s federal preemption defense, which argues that FDA’s rejection of a warning modification bars failure-to-warn claims. This hearing could be decisive in determining the fate of many cases.

September 2, 2025 – New Study Finds 2.43-fold Risk Increase Among Depo-Provera Users

The Journal of the American Medical Association published a study finding that women who took Depo-Provera were 2.43 times more likely to get a brain tumor. These findings are consistent with prior studies.

August 1, 2025 – New Study Reflects Risk of Meningioma Increases 3.5-fold After Depo-Provera

A recent study published in the medical journal Expert Opinion on Drug Safety found that use of Pfizer’s Depo-Provera for more than one year is associated with a 3.5-fold increased risk of developing an intracranial meningioma compared with the use of birth control pills. The study concluded that Depo-Provera’s active ingredient “is linked to a substantially increased risk of meningiomas, underscoring the importance of assessing its long-term use.”

July 1, 2025 – Judge Nixes State Court Consolidation in Philadelphia, PA

The only consolidated Depo-Provera litigation is occurring in the Northern District of Florida. However, the recent trend in mass torts is for non-leadership plaintiff firms to file cases in favorable state court venues and move to consolidate cases in those venues.

Philadelphia is considered one of the best plaintiff state court venues to consolidate a mass tort. Recently, we have seen huge verdicts come out of Philadelphia. To no one’s surprise, plaintiff attorneys filed lawsuits on behalf of nearly 100 plaintiffs in the Philadelphia Court of Common Pleas and sought consolidation. However, the judge disallowed consolidation and ordered the plaintiffs to refile individual lawsuits against Pfizer. It appears that the plaintiff attorneys have given up for now, as they have yet to refile those Depo-Provera lawsuits in Pennsylvania state court.

June 1, 2025 – CMO No. 23 Addresses Deficiencies in Plaintiffs’ Depo-Provera Complaints

Judge Rodgers’ most recent Case Management Order No. 23 establishes a formal process for addressing deficiencies in plaintiff complaints. Complaints must include a diagnosed meningioma linked to Depo-Provera use and complete jurisdictional information.

BrownGreer PLC, the Court-appointed data administrator, notifies plaintiffs of deficiencies, who then have two business days to amend. Non-compliant plaintiffs face a seven-day warning period, followed by an Order to Show Cause if unresolved.

May 8, 2025 – Depo-Provera Lawsuits Continue to Grow

The Depo-Provera multidistrict litigation continues to grow with more women filing lawsuits. In April 2025, a total of 52 new cases were filed into the MDL. This brings the total number of filed lawsuits to 130. Keep in mind that at this early stage, we usually only see very strong cases get filed. The reason is plaintiff attorneys do not want to file weaker cases that could get dismissed, which would give Pfizer momentum.

April 3, 2025 – Court Approves “Proof of Use” Questionnaire

In mass torts, one of the key issues is what constitutes proof of use or exposure. Obviously, if the claimant cannot prove that he or she used a product, then they cannot prove their claim. “Proof of use” is difficult if the use was decades ago or if documents reflecting use are not readily available. In some cases, proof of use can be an old photograph (e.g., hair relaxer litigation).

For the Depo-Provera litigation, the Court is requiring Plaintiffs to submit a “Plaintiff Proof of Use/Injury Questionnaire” within 120 days of March 14, 2025, or within 120 days of filing a lawsuit into the MDL. To help plaintiffs obtain documents, the Court’s order compels medical providers like pharmacies, hospitals, doctors’ offices, and health insurance companies to provide records reflecting the use of Depo-Provera.

Once again, Judge Rodgers is showing her experience, as her order helps streamline the “proof of use” requirement.

March 13, 2025 – Georgia Woman Files Depo-Provera Lawsuit Against Pfizer

A Georgia woman filed a Depo-Provera lawsuit alleging that birth control shots made by Pfizer caused her to develop meningioma brain tumors. According to the lawsuit, the plaintiff used Depo-Provera shots from 2008 to 2014 and was diagnosed with brain tumors in 2018. The case will transfer to the MDL (3140) in the Northern District of Florida.

March 1, 2025 – The Depo-Provera Litigation Is Moving Quickly

As we’ve said before, Judge Rodgers is a real pro presiding over MDLs. During the case management conference last week, Judge Rodgers told counsel that she wants the litigation to move fast. This is good for the plaintiffs, as the defense usually tries to delay as long as possible.

In addition, Judge Rodgers selected five “pilot cases” to move forward with discovery. She also wants to resolve important legal issues within 180 days. We anticipate that Judge Rodgers will lay out the scheduling of the litigation in more detail over the next few months. So far, the Depo-Provera MDL is moving faster than any other mass tort in history.

The next CMC is scheduled for March 10, 2025, at 9:00 a.m. CT.

February 24, 2025 – Judge Rodgers Enters Case Management Order No. 1

Judge Rodgers entered the first Case Management Order (“CMO”) in the Depo-Provera MDL. The CMO-1 addresses administrative matters and provides a general framework for MDL-3140.

Court to establish an MDL website. The Court is setting up a website, which will include an overview of the case, relevant orders, filings, dates, and other information.

Judge Rodgers selects five pilot cases to serve as test cases: Donna Toney v. Pfizer Inc. (Case No. 3:24cv624); Alicia Wilson v. Pfizer Inc. (Case No. 3:25cv100); Kristina Schmidt v. Pfizer Inc. (Case No. 3:25cv81); Rachel Valera-Arceo v. Pfizer Inc. (Case No. 3:25cv98); and Allison Blonski v. Pfizer Inc. (Case No. 3:25cv-00167).

Joint Rule 26 report and housekeeping. The Parties were required to hold an in-person Rule 26 meeting on March 3, 2025, with a Joint Rule 26 Report filed by March 7, 2025. The Court also directed the parties to discuss a direct-filing system into the MDL and an early proof-of-use and injury disclosure process applying to all Plaintiffs, including the pilot cases.

Plan for plaintiff leadership. Counsel were directed to submit a plan for Plaintiff leadership, consisting of committees including Lead Counsel, Liaison Counsel, an Executive Committee, a Steering Committee, Federal/State Liaison Counsel, and Settlement Counsel.

February 9, 2025 – Depo-Provera MDL Formed in Northern District of Florida

We officially have an MDL for the Depo-Provera lawsuits. In a curveball, the JPML formed MDL-3140 in Judge Casey Rodgers’ Court in the Northern District of Florida. Most lawyers (including us) thought the MDL would be formed in either New York or California. Pfizer wanted the MDL in New York, whereas a majority of the plaintiffs wanted the MDL in California. However, there was a late push by a smaller group of plaintiffs for federal court in Florida. Overall, we are pleased with the Northern District of Florida. Judge Rodgers is very experienced with complex MDLs, including the recent 3M earplug litigation.

We expect the next step of the litigation will entail appointing lawyers to serve on various committees and the start of discovery. Depo-Provera lawsuits filed in federal court in Georgia will now transfer to MDL-3140 in the Northern District of Florida.

February 1, 2025 – Medical Monitoring Class Action Filed Against Pfizer

A California woman filed a class action lawsuit in federal court in Pittsburgh demanding that the makers of Depo-Provera set up a “medical monitoring” database for women who used the birth control shots.

Medical monitoring is the concept that women who used Depo-Provera should have their medical monitoring expenses paid for by Pfizer and other defendants due to their increased risk of meningioma. In addition to creating a monitoring database, the Plaintiff in the class action wants Pfizer to cover ongoing treatment like MRIs that are necessary for doctors to look for and diagnose meningioma. If the class action is certified, Georgia women who used Depo-Provera would be able to get medical monitoring healthcare covered by Pfizer.

January 4, 2025 – Pfizer Wants Depo-Provera Lawsuits Consolidated in New York

There will be an MDL formed in the Depo-Provera lawsuits. The only question that remains is where. Pfizer has agreed that the Depo-Provera lawsuits should be centralized via MDL. However, Pfizer asked the JPML to consolidate the cases in the Southern District of New York. The Plaintiffs moved the JPML to consolidate in the Northern District of California.

Typically, a party wants to litigate in the venue with the most favorable variables (e.g., law, judges, convenience). In its briefing, Pfizer telegraphed its argument at the motion-to-dismiss stage: that it provided updated information about the drug’s side effects to the FDA, but the FDA would not allow Pfizer to change the warning label. This argument is called “preemption,” where claims arising under state law are barred because the product was approved by the FDA and its requirements were met. We think Pfizer prefers federal court in New York because the law and judges may be more favorable to its preemption defense than courts in California.

December 23, 2024 – Will an MDL Be Formed in the Depo-Provera Litigation?

A federal panel of judges (JPML) will meet in January 2025 to determine if the Depo-Provera cases should be consolidated under a single judge in a Multi-District Litigation (MDL). An MDL streamlines the litigation process when many similar claims are filed against the same company. Most cases so far have been filed in federal court in California. We will likely know if an MDL is formed by the end of February, and we expect that the JPML will consolidate.

November 13, 2024 – Depo-Provera Lawsuits Filed in Multiple Jurisdictions

Plaintiff firms have been very strategic about where they have filed Depo-Provera lawsuits. As of right now, the two preferred jurisdictions seem to be federal court in California and state court in Philadelphia, PA. In mass tort litigation, plaintiff firms usually file only the strongest cases at the beginning of the litigation in “good” venues. There is a lot of risk in drug litigation, and the misconception that plaintiff firms just file anything and everything could not be further from the truth.

Contact a Depo-Provera Lawyer Near Me in Atlanta, Georgia

At Fob James Law Firm, our job is to help you to the best of our ability and fight for you. If you’ve been diagnosed with a meningioma brain tumor, contact our Georgia Depo-Provera lawsuit lawyers immediately.

We can determine if you are eligible to file a lawsuit or not. It won’t cost you anything to speak with us. Additionally, you’ll never pay us anything until we successfully settle or win your case in court.

Our Atlanta, Georgia Depo-Provera lawyers are experienced, dedicated, and they truly care about you. We treat all of our clients exactly how we would want our own family members to be treated.

Contact us right now at 866-837-1010 or set up a free case evaluation so we can help you.

We serve Depo-Provera clients from our Atlanta office at 1718 Peachtree St NW, Suite 332, Atlanta, GA 30309, and throughout Georgia — including Atlanta, Savannah, Augusta, Columbus, Macon, Athens, Roswell, Sandy Springs, and Marietta.

Related Pages

• Depo-Provera Lawsuit Lawyer in Alabama
• Depo-Provera Lawsuit Lawyer in Tennessee
• Defective Products
• Dupixent Lawsuit Georgia
• Wrongful Death